Compare · AXNX vs SYK
AXNX vs SYK
Side-by-side comparison of Axonics Inc. (AXNX) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXNX and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $117.18B, about 56.4x AXNX ($2.08B).
- SYK has hit the wire 8 times in the past 4 weeks while AXNX has been quiet.
- SYK has more recent analyst coverage (25 ratings vs 21 for AXNX).
- Company
- Axonics Inc.
- Stryker Corporation
- Price
- $70.98+0.74%
- $301.60-1.32%
- Market cap
- $2.08B
- $117.18B
- 1M return
- -
- +2.47%
- 1Y return
- -
- -21.08%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 0
- 8
- Recent ratings
- 21
- 25
Axonics Inc.
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, France, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is headquartered in Irvine, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest AXNX
- RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors
- SEC Form 15-12G filed by Axonics Inc.
- SEC Form EFFECT filed by Axonics Inc.
- SEC Form 25-NSE filed by Axonics Inc.
- Director Kiernan Jane E returned $1,410,131 worth of shares to the company (19,861 units at $71.00), closing all direct ownership in the company (SEC Form 4)
- EVP, Chief Mktg/Strtgy Officer Woock John returned $5,495,613 worth of shares to the company (77,403 units at $71.00), closing all direct ownership in the company (SEC Form 4)
- Director Snyderman Nancy Lynn Md returned $1,061,024 worth of shares to the company (14,944 units at $71.00), closing all direct ownership in the company (SEC Form 4)
- Chief Operating Officer Sama Rinda returned $5,996,802 worth of shares to the company (84,462 units at $71.00), closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Noblett Karen returned $2,444,388 worth of shares to the company (34,428 units at $71.00), closing all direct ownership in the company (SEC Form 4)
- Director Lopez Esteban returned $468,600 worth of shares to the company (6,600 units at $71.00), closing all direct ownership in the company (SEC Form 4)
Latest SYK
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation